NEW DELHI: Drug firm Aurobindo Pharma BSE -1.40 pct has received approval from the U.S. health regulator to manufacture and market generic Norethindrone Acetate tablets in the American market.
The company has received the final nod from the US Food and Drug Administration (USFDA) to manufacture and market Norethindrone Acetate tablets in the strength of 5 mg, Aurobindo Pharma said in a statement.
"The approved product has an estimated market size of USD 24 million for the 12 months ending November 2015 according to IMS," it added.
The company's product is generic version of Duramed Pharmaceuticals Aygestin tablets in the same strength, Aurobindo Pharma said.
"Norethindrone Acetate tablet is used in the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels and secondary amenorrhea," it added.
The company has a total of 230 abbreviated new drug application ( ANDA) approvals (199 final approvals including 10 from Aurolife Pharma LLC and 31 tentative approvals) from the USFDA.
Shares of Aurobindo Pharma were trading at Rs 838.40, down 0.92 per cent in the afternoon trade on BSE.
Also Read:
'External Storage Market Witnesses Significant Growth'
India Inc Pushes for FDI in Multi-Brand; Raises Concern on Free-Trade Pacts
